A detailed history of Holocene Advisors, LP transactions in Argenx Se stock. As of the latest transaction made, Holocene Advisors, LP holds 195,104 shares of ARGX stock, worth $123 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
195,104
Previous 425,614 54.16%
Holding current value
$123 Million
Previous $183 Million 42.19%
% of portfolio
0.46%
Previous 0.81%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $100 Million - $127 Million
-230,510 Reduced 54.16%
195,104 $106 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $22.5 Million - $28.5 Million
-63,186 Reduced 12.93%
425,614 $183 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $14.2 Million - $16.5 Million
-39,898 Reduced 7.55%
488,800 $192 Million
Q4 2023

Feb 14, 2024

BUY
$338.91 - $506.01 $53.1 Million - $79.2 Million
156,543 Added 42.06%
528,698 $201 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $5.13 Million - $7.62 Million
13,899 Added 3.88%
372,155 $183 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $8.12 Million - $9.52 Million
22,534 Added 6.71%
358,256 $140 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $58.4 Million - $70.6 Million
-174,870 Reduced 34.25%
335,722 $125 Million
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $841,738 - $989,682
-2,460 Reduced 0.48%
510,592 $193 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $3.35 Million - $3.87 Million
-9,769 Reduced 1.87%
513,052 $181 Million
Q2 2022

Aug 15, 2022

SELL
$269.58 - $378.88 $1.73 Million - $2.43 Million
-6,403 Reduced 1.21%
522,821 $198 Million
Q1 2022

May 16, 2022

BUY
$254.45 - $351.06 $86.3 Million - $119 Million
338,995 Added 178.2%
529,224 $167 Million
Q4 2021

Feb 14, 2022

BUY
$272.01 - $353.03 $51.7 Million - $67.2 Million
190,229 New
190,229 $66.6 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $35B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Holocene Advisors, LP Portfolio

Follow Holocene Advisors, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on Holocene Advisors, LP with notifications on news.